Compares two antibiotic treatments for lung flare-ups in cystic fibrosis
Compares one antibiotic type with two types for cystic fibrosis lung flare-ups.
Key facts
- Who runs it
- Chris Goss
- Where
- Akron, Ann Arbor, Atlanta, Baltimore, Billings, Birmingham, Boise, Boston, Charleston, Chicago, Cincinnati, Cleveland, Columbus, Dallas, Dayton, Fort Worth, Gainesville, Grand Rapids, Hollywood, Indianapolis, Iowa City, Jacksonville, Kansas City, La Jolla, Lebanon, Long Beach, Louisville, Madison, Miami, Morgantown, Morristown, Nashville, New Brunswick, New York, Oklahoma City, Orange, Peoria, Philadelphia, Pittsburgh, Portland, Richmond, Sacramento, Seattle, Spokane, St Louis, St. Petersburg, Toledo, Tucson, Valhalla, Washington D.C., and Worcester, United StatesSee the 59 sitesAlso in 1 other country, 1 site
- Trial code
- Registry title
- Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 730 people, planned
- Started
- 23 Apr 2023
- Expected to end
- 31 May 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- Beta-lactam antibiotic
- Aminoglycoside
- Record updated
- 8 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 6 or older with cystic fibrosis who have a lung flare-up and will get 14 days of IV antibiotics.
- Age
- 6 years or older
- Sex
- All genders can join
- Disease stage
- A cystic fibrosis lung flare-up (pulmonary exacerbation) that the doctor plans to treat with a 14-day course of IV antibiotics
- Earlier treatment
- No IV antibiotics, ICU stay, pneumothorax or coughing up blood within 6 weeks before Visit 1. No investigational therapies, new CFTR modulators or treatment for nontuberculous mycobacteria (NTM) within 4 weeks before Visit 1. No more than one day of IV aminoglycosides for the current flare-up before Visit 1.
- Biomarker or test result
- At least one documented Pa positive culture within two years before Visit 1
Main reasons for not taking part
- Pregnancy
- Known kidney problems or a past solid organ transplant
- History of allergy, balance or hearing damage from aminoglycosides
- Use of investigational therapies or new CFTR modulators within 4 weeks before Visit 1
- More than one day of IV aminoglycosides for the current flare-up before Visit 1
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- All genders ≥ 6 years of age at Visit 1
- Documentation of a CF diagnosis
- Clinician intent to treat index CF PEx with a planned 14-day course of IV antimicrobials
- At least one documented Pa positive culture within two years prior to Visit 1
Who cannot take part
- No IV antimicrobial treatment, ICU admission, pneumothorax, or hemoptysis within 6 weeks prior to Visit 1
- No use of investigational therapies, new CF transmembrane conductance regulator (CFTR) modulators, or treatment for Nontuberculous mycobacteria (NTM) within 4 weeks prior to Visit 1
- No more than one day of IV aminoglycosides administered for the current PEx treatment prior to Visit 1
- No known renal impairment or history of solid organ transplantation
- No history of hypersensitivity, vestibular, or auditory toxicity with aminoglycosides
- Participant is not pregnant
Where in United States
Also in 1 other country, 1 site
- Children's Hospital Medical Center of AkronAkron, United StatesContact: Michelle ParrishTaking people
- University of Michigan - Michigan MedicineAnn Arbor, United StatesContact: Dawn KruseTaking people
- Emory UniversityAtlanta, United StatesContact: Ashleigh StrebyTaking people
- John Hopkins HospitalBaltimore, United StatesContact: Jeanne PintoTaking people
- Billings ClinicBillings, United StatesContact: Jerimiah LysingerTaking people
- The Children's Hospital Alabama & University of Alabama at BirminghamBirmingham, United StatesContact: Heather HathorneTaking people
- Saint Luke's Cystic Fibrosis Center of IdahoBoise, United StatesContact: Lejla GodusevicTaking people
- Boston Children's Hospital, Brigham & Women's HospitalBoston, United StatesContact: Robert FowlerTaking people
- Medical University of South CarolinaCharleston, United StatesContact: Ashley WardenTaking people
- Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesContact: Yung Hsuan (Irene) WuTaking people
- Northwestern UniversityChicago, United StatesContact: Rachel NelsonTaking people
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Kelly ThorntonTaking people
- University of Cincinnati Medical CenterCincinnati, United StatesContact: Nicole HummelTaking people
- Rainbow Babies and Children's Hospital / University Hospitals Cleveland Medical CenterCleveland, United StatesContact: Rachael Buckingham, BSTaking people
- Nationwide Children's HospitalColumbus, United StatesContact: Diana GilmoreTaking people
- University of Texas Southwestern, Children's HealthDallas, United StatesContact: Mary KlostermanTaking people
- University of Texas, SouthwesternDallas, United StatesContact: Ashley KellerTaking people
- Dayton Children's HospitalDayton, United StatesContact: Amy JonesTaking people
- Cook Children's Medical CenterFort Worth, United StatesContact: Jill FintoTaking people
- University of FloridaGainesville, United StatesContact: Melissa LingisTaking people
- Helen DeVos Children's HospitalGrand Rapids, United StatesContact: Andrew JamesTaking people
- Joe DiMaggio Children's HospitalHollywood, United StatesContact: Norma (Jean) BartonTaking people
- Indiana University Medical CenterIndianapolis, United StatesContact: Lisa BendyTaking people
- Riley Hospital for ChildrenIndianapolis, United StatesContact: Lisa BendyTaking people
- University of IowaIowa City, United StatesContact: Mary TeresiTaking people
- Nemours Children's ClinicJacksonville, United StatesContact: Jennifer (Jenn) GaffordTaking people
- University of Kansas Medical CenterKansas City, United StatesContact: Lawrence ScottTaking people
- University of California San DiegoLa Jolla, United StatesContact: Jenna Mielke,Taking people
- Dartmouth Hitchcock Medical CenterLebanon, United StatesContact: Barbara A RodgersTaking people
- Long Beach Memorial Medical CenterLong Beach, United StatesContact: Marylee MelendrezTaking people
- University of LouisvilleLouisville, United StatesContact: Melissa ThomasTaking people
- University of WisconsinMadison, United StatesContact: Melanie NelsonTaking people
- University of MiamiMiami, United StatesContact: Ylber WhitakerTaking people
- West Virginia University - MorgantownMorgantown, United StatesContact: Tammy ClarkTaking people
- Morristown Medical CenterMorristown, United StatesContact: Debra ConnollyTaking people
- Vanderbilt Children's HospitalNashville, United StatesContact: Brijesh PatelTaking people
- Rutgers, Robert Wood Johnson Medical SchoolNew Brunswick, United StatesContact: Sheila Redding, SheilaTaking people
- Children's Hospital of New YorkNew York, United StatesContact: Hossein SadeghiTaking people
- Lenox Hill Hospital Cystic Fibrosis CenterNew York, United StatesContact: Teresa DemarcoTaking people
- Oklahoma Cystic Fibrosis CenterOklahoma City, United StatesContact: Rachael Buckingham, BSTaking people
- CHOC Children's HospitalOrange, United StatesContact: Lila KleinTaking people
- OSF Saint Francis Medical CenterPeoria, United StatesContact: Ashley ScottTaking people
- University of PennsylvaniaPhiladelphia, United StatesContact: Melissa MolterTaking people
- Children's Hospital of Pittsburgh of UPMCPittsburgh, United StatesContact: Elizabeth HartiganTaking people
- Maine Medical CenterPortland, United StatesContact: Harmony RennaTaking people
- Oregon Health Sciences UniversityPortland, United StatesContact: Jenna BucherTaking people
- Virginia Commonwealth UniversityRichmond, United StatesContact: Akilah Pierre-LouisTaking people
- University of California at Davis Medical CenterSacramento, United StatesContact: Daniel Diaz-VigilTaking people
- Seattle Children's HospitalSeattle, United StatesContact: Sharon McNamaraTaking people
- University of Washington Medical CenterSeattle, United StatesContact: Lauren BartlettTaking people
- Providence Medical Group, Cystic Fibrosis ClinicSpokane, United StatesContact: Joan MiltonTaking people
- SSM Health Cardinal Glennon Children's HospitalSt Louis, United StatesContact: Freda BranchTaking people
- Washington University School of MedicineSt Louis, United StatesContact: Irma BauerTaking people
- All Children's HospitalSt. Petersburg, United StatesContact: Diana HodgeTaking people
- Toledo Children's HospitalToledo, United StatesContact: Kelly HootTaking people
- Tucson Cystic Fibrosis CenterTucson, United StatesContact: Elizabeth RyanTaking people
- New York Medical College at Westchester Medical CenterValhalla, United StatesContact: Zachary MesserTaking people
- Children's National Medical CenterWashington D.C., United StatesContact: Jack SerioNot yet recruiting
- University of Massachusetts Memorial Health CareWorcester, United StatesContact: Jaclyn LongtineTaking people
About the trial
What the trial wants to find out
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs medical intervention. Both doctors and CF patients are trying to understand the best way to treat pulmonary exacerbations. This study is trying to answer the following questions about treating a pulmonary exacerbation:
Read full original descriptionShow less
* Do participants have the same improvement in lung function and symptoms if they are treated with one type of antibiotic (called beta-lactams or β-lactams) versus taking two different types of antibiotics (tobramycin and β-lactams)? * Is taking one type of antibiotic just as good as taking two types?
The 2 groups in the trial
- β-lactam Only (Non-AG)Other group
Participants randomized to this arm will be prescribed a standard of care intravenous (IV) β-lactam as selected by their treating physician. Treatment must not include an IV aminoglycoside.
Treatment: Beta-lactam antibiotic
- β-lactam and Aminoglycoside (AG)Other group
Participants randomized to this arm will be prescribed a standard of care intravenous (IV) β-lactam and aminoglycoside selected by their treating physician.
Treatment: Beta-lactam antibiotic and Aminoglycoside
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Standardizing Treatments for Pulmonary Exacerbations: A Platform for Evaluating Treatment Decisions to Improve Outcomes (STOP360) Aminoglycoside Study (AG Study)
- Plain-language title
- Compares two antibiotic treatments for lung flare-ups in cystic fibrosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 8 July 2026